Scalable Symptom Monitoring Intervention May Up Asthma-Related QoL in Subgroup of Adults
By Elana Gotkine HealthDay Reporter
THURSDAY, May 8, 2025 -- A scalable symptom monitoring intervention increases asthma-related quality of life in adults, according to a study published online April 23 in JAMA Network Open.
Robert S. Rudin, Ph.D., from RAND in Boston, and colleagues examined the effect of a scalable asthma symptom monitoring intervention on asthma outcomes in a randomized clinical trial involving adults with a diagnosis of asthma between July 2020 and March 2023. Patients were categorized into tiers of varying disease activity. Intervention group patients completed weekly symptom questionnaires and viewed educational information. Usual care group patients received general asthma guidance. The primary analysis included 366 patients.
The researchers found that the Mini Asthma Quality of Life Questionnaire (MiniAQLQ) score increased 0.34 and 0.11 in the intervention and usual care groups, respectively, from baseline to completion of the final questionnaire (adjusted difference-in-difference, 0.23); the difference was statistically significant but did not meet the threshold for minimally important change. Relative to the usual care group, intervention subgroups showed positive differences in MiniAQLQ scores, with noteworthy increases among individuals aged 18 to 44 years, those with low baseline patient activation, those with a low baseline MiniAQLQ score, and those with uncontrolled asthma at baseline (adjusted difference-in-differences, 0.40, 0.77, 0.33, and 0.30, respectively). The intervention and usual care groups had a mean of 0.59 and 0.76 nonroutine asthma-related utilization events, respectively.
“Overall, these data suggest that the between-visit symptom monitoring led to an average improvement in asthma quality of life among study patients, although this improvement did not meet the threshold of a minimally important change,” the authors wrote. “However, the intervention showed potential benefits for certain subgroups and may be useful in other chronic diseases in which between-visit symptoms are important.”
Two authors disclosed ties to industry; one reported holding a related patent.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Emergency Department Visits for Asthma Increased During 2023 Wildfires
MONDAY, May 5, 2025 -- Increases in asthma-related emergency department visits were seen in Ontario in association with the 2023 wildfires, according to a study published online...
Withdrawal of Flovent Led to Discontinuation of Inhaled Steroids for Children With Asthma
FRIDAY, May 2, 2025 -- For children using fluticasone propionate, the withdrawal of the brand-name drug (Flovent) was associated with increased discontinuation of inhaled steroid...
Exposure to Smoke Pollution Ups Risk for Hospitalization for Respiratory Disease
FRIDAY, May 2, 2025 -- For older adults in the Western United States, exposure to high levels of smoke pollution is associated with an increase in hospitalizations for respiratory...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.